21 Active Studies

Pulmonary Fibrosis Clinical Trials

Find actively recruiting research studies for pulmonary fibrosis. Connect with study sites near you and explore new treatment options.

21
Active Trials
74+
Locations
6,877
Participants Needed

Recruiting Studies

RecruitingNCT06238622

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medic...

10 locations(Birmingham, Tucson, Los Angeles)
1,700 participants
Boehringer Ingelheim
View Study Details
RecruitingNCT06025578

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis....

10 locations(Birmingham, Phoenix, Phoenix)
1,092 participants
Bristol-Myers Squibb
View Study Details
RecruitingNCT05943535

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period....

10 locations(Birmingham, Phoenix, Los Angeles)
698 participants
United Therapeutics
View Study Details
RecruitingNCT06572384

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Interstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, ...

10 locations(Los Angeles, Los Angeles, Los Angeles)
440 participants
GlaxoSmithKline
View Study Details
RecruitingNCT06195072

Platform Clinical Study for Conquering Scleroderma

The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung ...

10 locations(Birmingham, Los Angeles, Los Angeles)
400 participants
Scleroderma Research Foundation, Inc.
View Study Details
RecruitingNCT06806592

A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases

Adults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improve...

10 locations(Birmingham, Scottsdale, Los Angeles)
400 participants
Boehringer Ingelheim
View Study Details
RecruitingNCT05785624

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with system...

10 locations(Birmingham, Phoenix, Tucson)
320 participants
Genentech, Inc.
View Study Details
RecruitingNCT06329401

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants wit...

10 locations(Birmingham, Phoenix, Los Angeles)
300 participants
Avalyn Pharma Inc.
View Study Details
RecruitingNCT05878717

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lun...

10 locations(Phoenix, Scottsdale, Scottsdale)
300 participants
GlaxoSmithKline
View Study Details
RecruitingNCT06588686

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, ei...

10 locations(Birmingham, Los Angeles, Redding)
270 participants
Vicore Pharma AB
View Study Details
RecruitingNCT06967805

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF)...

8 locations(Phoenix, Newport Beach, Palm Springs)
164 participants
Mediar Therapeutics
View Study Details
RecruitingNCT04855305

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung disea...

4 locations(Iowa City, Durham, Cincinnati)
147 participants
Bastiaan Driehuys
View Study Details
RecruitingNCT05571059

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Ifetroban prevents and treats lung fibrosis due to multiple causes (bleomycin, genetic, radiation). The safety and efficacy of oral ifetroban will be assessed in patients with IPF....

10 locations(San Francisco, Jacksonville, Miami)
128 participants
Cumberland Pharmaceuticals
View Study Details
RecruitingNCT06635850

A Study of Mosliciguat in PH-ILD

This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension asso...

10 locations(Phoenix, Los Angeles, Sacramento)
120 participants
Pulmovant, Inc.
View Study Details
RecruitingNCT05389215

Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF

This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis....

10 locations(Mesa, Phoenix, San Francisco)
102 participants
Daewoong Pharmaceutical Co. LTD.
View Study Details
RecruitingNCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adj...

10 locations(Birmingham, San Diego, Santa Rosa)
100 participants
Reunion Neuroscience Inc
View Study Details
RecruitingNCT05975983

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn about INS018\_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018\_055 orall...

10 locations(Birmingham, Scottsdale, Los Angeles)
60 participants
InSilico Medicine Hong Kong Limited
View Study Details
RecruitingNCT05350371

Safety and Tolerability of Pirfenidone in Acute Pancreatitis

The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis. Pirfenidone is curren...

2 locations(Birmingham, Rochester)
60 participants
University of Alabama at Birmingham
View Study Details
RecruitingNCT04925375

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promis...

6 locations(San Francisco, Tampa, Burlington)
38 participants
Children's Hospital Medical Center, Cincinnati
View Study Details
RecruitingNCT05892614

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary ob...

10 locations(Los Angeles, San Diego, Miami)
25 participants
aTyr Pharma, Inc.
View Study Details
RecruitingNCT05783323

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioacti...

5 locations(San Francisco, Philadelphia, Memphis)
13 participants
Children's Hospital of Philadelphia
View Study Details

Frequently Asked Questions

What clinical trials are available for Pulmonary Fibrosis?

There are currently 21 actively recruiting clinical trials for pulmonary fibrosis. These studies are testing new treatments, therapies, and interventions at research sites across 74 cities.

How do I join a Pulmonary Fibrosis clinical trial?

To join a pulmonary fibrosis clinical trial: 1) Browse the available studies above, 2) Click on a study that interests you, 3) Complete the eligibility form, and 4) A study coordinator will contact you.

Are clinical trials free for patients?

Yes, clinical trial participation is free. In most studies, the treatment, medical tests, and doctor visits related to the trial are provided at no cost. Some studies may also compensate for time and travel.

Can I leave a clinical trial if I change my mind?

Yes, participation in any clinical trial is completely voluntary. You can withdraw at any time, for any reason, without affecting your regular medical care.